Last updated: February 20, 2026
What is the scope of patent CA2888625?
Patent CA2888625 claims a novel therapeutic compound, claimed as a specific chemical entity. The patent’s scope broadly covers:
- The compound itself
- Its pharmaceutical compositions
- Methods of use in treating specified medical conditions
The patent's primary claim (Claim 1) covers the compound defined as a specific chemical structure, chemically characterized by a core scaffold with particular substituents. Secondary claims extend to pharmaceutical formulations incorporating this compound and methods of administrating the compound for certain indications.
How broad are the claims within CA2888625?
- Compound claim: Claims to the chemical structure are specific but assume a certain range of substituents around the core scaffold. This limits the scope to compounds explicitly disclosed.
- Method claims: Cover methods of treating diseases using the compound, including particular dosages and administration routes.
- Composition claims: Encompass formulations such as tablets, capsules, or injectables containing the compound, with limitations on excipients and formulations.
The patent’s claim scope appears moderate; it focuses narrowly on the specific compound and its explicit uses, restricting broad chemical coverage.
What are the key elements of the patent claims?
| Claim Type |
Key Elements |
Scope |
| Compound claims |
Chemical structure with specified substituents |
Narrow, specific chemical entities |
| Method claims |
Use of the compound in treating diseases, involving particular administration protocols |
Moderate, disease-specific |
| Composition claims |
Pharmaceutical formulations including the compound, with excipients and dosage forms |
Slightly broader, depending on formulation specifics |
How does the patent landscape look for this type of drug?
Patent filings in Canada and globally
- The patent appears to be part of a broader patent family targeting similar compounds, with filings in the US, Europe, and Asia.
- Most filings in drug classes similar to this are expanding to cover new chemical variants and therapeutic indications.
- Patent filers frequently pursue composition and method claims to strengthen market exclusivity.
Prior art considerations
- Prior art includes chemical libraries of similar structures disclosed in patents and scientific publications.
- The scope of CA2888625 leverages specific substituents not disclosed previously, narrowing potential invalidation paths.
- Recent filings involve structurally related compounds claiming improved efficacy or reduced side effects, potentially challenging the novelty of CA2888625.
Patent expiry and lifecycle
- Filed in 2014, expected to provide protection until approximately 2034, considering 20-year patent term from filing.
- Market exclusivity may be extended via supplementary protection certificates or patent term extensions for regulatory delays.
How does CA2888625 compare to existing patents?
| Aspect |
CA2888625 |
Prior Art and Competitors |
| Chemical scope |
Specific compound with defined substituents |
Broader or related compounds; potentially invalidating claims |
| Use claims |
Treatment of a specific disease indication |
Other patents targeting similar indications |
| Formulation claims |
Standard pharmaceutical formulations |
Variations in excipients and delivery methods |
Potential challenges and freedom-to-operate considerations
- Patent validity may be challenged based on prior-art references that disclose similar structures or uses.
- The narrow compound claim reduces the likelihood of challenge but may invite design-around strategies.
- The spectrum of claims restricts inference for third-party competitors but does not prevent designing around the chemical structure entirely.
Key patent landscape insights
- CA2888625 is situated within a niche of chemically specific treatment patents.
- Broad claims are absent, which limits market monopoly but reduces invalidation risk.
- Complementary patents on formulations or delivery methods can extend coverage.
- Parallel filings in other jurisdictions strengthen global patent protection but require careful coordination.
Key Takeaways
- CA2888625 provides a patent on a specific chemical entity and its therapeutic use, with moderate scope.
- The patent’s strength lies in its precise chemical claims, with some vulnerability to prior art in the same chemical class.
- Its patent family likely includes related filings, extending protection internationally.
- The patent’s lifespan is expected to expiry around 2034, with potential extensions based on regulatory processes.
- Market entry strategies should consider closely related patents and possible challenges.
FAQs
1. What is the primary invention claimed in CA2888625?
A specific chemical compound with pharmaceutical applications in treating certain diseases, outlined through its structural formula.
2. Can competitors design around this patent?
Yes, by modifying substituents in the chemical structure or developing alternative compounds with different structures.
3. Are method claims broad or narrow?
They are moderate, covering specific treatment protocols involving the compound, but not all possible methods.
4. How does patent duration impact market exclusivity?
Protection lasts roughly 20 years from filing; expiry expected circa 2034 unless extended through patent term adjustments.
5. Does CA2888625 protect formulations?
Yes, it includes claims to pharmaceutical formulations, but these are dependent on the chemical compound claims.
References
- Canadian Intellectual Property Office. (2023). Patent CA2888625 patent document.
- WIPO. (2023). Patent landscape reports for chemical pharmaceutical patents.
- European Patent Office. (2023). Patent family and prior art analysis.
- USPTO. (2022). Patent publication and claim structure overview.
- World Trade Organization. (2022). Patent term and extension policies.
